Lexicon Pharmaceuticals Inc. (LXRX)
Symbol Info
Listed Symbol LXRX
Name Lexicon Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $62,887,000
Latest Fiscal EPS $-1.14
Price Info
21 Day Moving Average $1.4938
21 Day EMA $1.786060
50 Day Moving Average $2.8504
50 Day EMA $2.638640
200 Day EMA $5.311010
200 Day Moving Average 5.392450
52 Week High $11.51
52 Week Low $1.13
52 Week Change $-78.413300
Alpha -0.003340
Beta 0.9433
Standard Deviation 0.214069
R2 0.023080
Periods 60
Share Information
10 Day Average Volume 3,071,520
20 Day Average Volume 1,858,946
30 Day Average Volume 1,867,072
50 Day Average Volume 1,974,808
Outstanding Shares 106,271,927
Float Shares 104,274,577
Percent Float 98.12%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 255
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 2,200,698
Institute Holdings Percent -
Institute Sold Previous 3 Months 4,504,244
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 11
Insider Holdings Percent 1.90%
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,997,350
Price Change
7 Day Price Change $0.9599999
7 Day Percent Change 69.57%
21 Day Price Change $1.0400000
21 Day Percent Change 80.00%
30 Day Price Change $0.8799999
30 Day Percent Change 60.27%
Month To Date Price Change $1.0200
Month To Date Percent 77.27%
90 Day Price Change $-3.52
90 Day Percent Change -60.07%
Quarter To Date $-3.95
Quarter To Date Percent -62.80%
180 Day Price Change $-5.520001
180 Day Percent Change -70.23%
200 Day Price Change $-3.15
200 Day Percent Change -57.38%
Year To Date $-4.3
Year To Date Percent -64.76%
Profile
Description Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising drug targets. Lexicon then designs and develops drugs for these targets, which cover a broad spectrum of therapeutic areas. Following a restructuring in January 2014, Lexicon focused efforts on two drugs: sotagliflozin in diabetes, which is partnered with Sanofi, and Xermelo (telotristat etiprate) in carcinoid syndrome, which is partnered with Ipsen outside the U.S. Early-stage programs include SGLT1 inhibitor LX2761 and neuropathic pain drug LX9211.
Details
Issue Type CS
Market Cap $248,676,309
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 106,271,927
CEO Lonnel Coats
Employees 202
Last Audit UE
Classification
CIK 0001062822
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 8800 Technology Forest Place
The Woodlands, TX 77381
Website http://www.lexpharma.com
Facisimile +1 281 863-8088
Telephone +1 281 863-3000
Email
Key Ratios
Profitability
EBIT Margin -158.9
EBITDA Margin -150.4
Pre-Tax Profit Margin -192
Profit Margin Cont -
Gross Margin 93.00
Profit Margin TOT -
Income Statements
Revenue $42,825,000
Revenue Per Share $0.4030
Revenue 3 Years $-23.44
Revenue 5 Years $36.14
Valuation Measures
PE Ratio -
Enterprise Value $396,269,063
Price To Sales 5.806802
Price To Free Cash -2.5
PE High Last 5 Years -
Price To Book 48.5
Price To Cash Flow 12.0
PE Low Last 5 Years -
Price To Tangible Book -1.6
Financial Strength
Total Debt To Equity -
Int Coverage -3.3
Current Ratio 5.5
Leverage Ratio -6.5
Quick Ratio 5.0
Long Term Debt To Capital -
Assets
Receivables Turnover 2.9
Invoice Turnover 0.90
Assets Turnover -
Management Effectiveness
Return Assets -31.44
Return On Equity 254.42
Return On Capital -
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type
Your Recent History
NASDAQ
LXRX
Lexicon Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20190915 10:40:00